NCT01286077 · OUTCOME

Appearance of New Bone Lesions Compared to Baseline

Velcade Consolidation Bone Study · Source last updated 2016-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Appearance of new bone lesions assessed by skeletal survey compared to baseline

Analysis population: Data could not be summarised statistically due to insufficient data at End of treatment.

bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles

no treatment, observation only

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Bortezomib	46
Non-treated Control	47

Source class 1

Values in subjects · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Bortezomib	0	Not reported	Not reported	Not reported	Not reported
Non-treated Control	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Appearance of new bone lesions assessed by skeletal survey compared to baseline

groups

param Type

NUMBER

population Description

Data could not be summarised statistically due to insufficient data at End of treatment.

reporting Status

POSTED

time Frame

Baseline up to end of study (approximately 4 years 7 months)

title

Appearance of New Bone Lesions Compared to Baseline

type

SECONDARY

unit Of Measure

subjects

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice